XML 39 R22.htm IDEA: XBRL DOCUMENT v3.22.2.2
Revenue Recognition (Tables)
 9 Months Ended
Sep. 30, 2022
Revenue from Contract with Customer [Abstract]  
Disaggregation of Revenue
Segment information is as follows (in thousands):
Three Months Ended September 30, 2022Three Months Ended September 30, 2021
Performance EnzymesNovel BiotherapeuticsTotalPerformance EnzymesNovel BiotherapeuticsTotal
Major products and service:
       Product revenue$28,042 $— $28,042 $28,731 $— $28,731 
Research and development revenue3,104 3,324 6,428 3,853 4,185 8,038 
Total revenues$31,146 $3,324 $34,470 $32,584 $4,185 $36,769 
Primary geographical markets:
Americas$3,654 $1,168 $4,822 $5,999 $1,817 $7,816 
EMEA3,831 2,156 5,987 2,317 2,368 4,685 
APAC23,661 — 23,661 24,268 — 24,268 
Total revenues$31,146 $3,324 $34,470 $32,584 $4,185 $36,769 
Nine Months Ended September 30, 2022Nine Months Ended September 30, 2021
Performance EnzymesNovel BiotherapeuticsTotalPerformance EnzymesNovel BiotherapeuticsTotal
Major products and service:
       Product revenue$93,376 $— $93,376 $53,674 $— $53,674 
Research and development revenue7,398 7,441 14,839 14,723 11,856 26,579 
Total revenues$100,774 $7,441 $108,215 $68,397 $11,856 $80,253 
Primary geographical markets:
Americas$8,514 $3,653 $12,167 $12,573 $6,015 $18,588 
EMEA11,017 3,788 14,805 11,294 5,841 17,135 
APAC81,243 — 81,243 44,530 — 44,530 
Total revenues$100,774 $7,441 $108,215 $68,397 $11,856 $80,253 
Contract with Customer The following table presents balances of contract assets, unbilled receivables, contract costs, and contract liabilities (in thousands):
September 30, 2022December 31, 2021
Contract assets$5,867 $4,557 
Unbilled receivables$7,490 $8,558 
Contract costs$28 $56 
Contract liabilities: deferred revenue$9,840 $6,335 
We recognized the following revenues (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
Revenue recognized in the period for:2022202120222021
Amounts included in contract liabilities at the beginning of the period:
     Performance obligations satisfied$889 $658 $1,694 $1,997 
Changes in the period:
Changes in the estimated transaction price allocated to performance obligations satisfied in prior periods495 1,521 365 5,848 
Performance obligations satisfied from new activities in the period - contract revenue33,086 34,590 106,156 72,408 
Total revenues$34,470 $36,769 $108,215 $80,253 
Performance Obligation, Expected Timing of Satisfaction
The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting periods. The estimated revenue does not include contracts with original durations of one year or less, amounts of variable consideration attributable to royalties, or contract renewals that are unexercised as of September 30, 2022.
The balances in the table below are partially based on judgments involved in estimating future orders from customers subject to the exercise of material rights pursuant to respective contracts as of September 30, 2022 (in thousands):
Remainder of 2022
20232024
2025 and Thereafter
Total
Product revenue$5 $127 $5,276 $2,962 $8,370 
Research and development revenue423 1,047 — — 1,470 
Total revenues$428 $1,174 $5,276 $2,962 $9,840